GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of "Moderate Buy" from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.18.

GDRX has been the subject of several recent analyst reports. KeyCorp dropped their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Wells Fargo & Company lowered their price objective on GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Morgan Stanley dropped their price target on GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Tuesday, December 17th. Finally, Citigroup cut their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research note on Friday, January 10th.

Institutional Investors Weigh In On GoodRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. National Bank of Canada FI raised its position in GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after acquiring an additional 2,151 shares during the period. RPO LLC purchased a new stake in GoodRx in the 4th quarter worth approximately $52,000. Versor Investments LP bought a new stake in GoodRx during the fourth quarter valued at $54,000. Verus Capital Partners LLC purchased a new position in shares of GoodRx during the fourth quarter worth about $55,000. Finally, Steward Partners Investment Advisory LLC purchased a new stake in shares of GoodRx during the 4th quarter valued at $56,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

Remove Ads

GoodRx Price Performance

Shares of NASDAQ:GDRX traded down $0.24 during midday trading on Tuesday, hitting $4.06. The stock had a trading volume of 672,778 shares, compared to its average volume of 1,364,104. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.56 billion, a P/E ratio of -135.83, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company's 50-day moving average price is $4.74 and its 200-day moving average price is $5.22. GoodRx has a fifty-two week low of $4.01 and a fifty-two week high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.